Equity Profile

KRYS

Krystal Biotech, Inc.

Health CareBiotechnology$8.9B

Mar18Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is crucial for assessing future performance.

Not available

Wall Street expectations, options signals, track record, and call prep available with Pro.

KRYS Q2-2026 Earnings Preview

Context

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for rare diseases. Operating in the health care sector, its innovative approaches could significantly impact patient care and treatment options in the biotechnology industry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In the last quarter, Krystal Biotech reported an EPS of $1.83, exceeding expectations by 26.21%. The stock reacted positively, gaining 7.86% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Krystal Biotech's upcoming earnings are mixed, with no consensus estimates available. Investors are keen to see if the company can maintain its recent positive momentum.

Bull Case

If Krystal Biotech continues to beat EPS expectations, it could signal strong demand for its products and lead to further stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a significant drop in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $1.83, and by how much?

Given the company's recent performance, a higher EPS could indicate sustained growth and investor confidence.

What are the revenue figures for this quarter?

Revenue growth is critical for assessing the company’s market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Krystal Biotech to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% success rate in the last eight quarters.

Options pricing suggests a limited move, indicating that the market may not fully anticipate a significant upside.

Key Risk

If the EPS comes in above $1.90, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce the recent positive trends or highlight potential weaknesses.

Bull Confirmed If

An EPS of $1.90 or higher would confirm strong growth and investor confidence.

Bear Confirmed If

An EPS below $1.70 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±3.35%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move of about 3.35%, suggesting that traders expect limited volatility around the earnings announcement.

Options are pricing ±3.3% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

38.7%

Calls (1K)P/C Ratio: 0.13Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal Biotech beats expectations, history suggests the stock could rise by an average of 2.6%, confirming a positive growth outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 14.05%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into customer adoption rates for recent therapies.
4Guidance on future revenue expectations and growth strategies.
5Details on any potential partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Gen Digital Inc.

Company Snapshot

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Not available

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is crucial for assessing future performance.

Not available

Wall Street expectations, options signals, track record, and call prep available with Pro.

KRYS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+23.84%

Avg Stock Reaction

-1.56%

Last Quarter Recap

In the last quarter, Krystal Biotech reported an EPS of $1.83, exceeding expectations by 26.21%. The stock reacted positively, gaining 7.86% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Krystal Biotech's upcoming earnings are mixed, with no consensus estimates available. Investors are keen to see if the company can maintain its recent positive momentum.

Bull Case

If Krystal Biotech continues to beat EPS expectations, it could signal strong demand for its products and lead to further stock price appreciation.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a significant drop in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $1.83, and by how much?

Given the company's recent performance, a higher EPS could indicate sustained growth and investor confidence.

What are the revenue figures for this quarter?

Revenue growth is critical for assessing the company’s market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Krystal Biotech to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% success rate in the last eight quarters.

Options pricing suggests a limited move, indicating that the market may not fully anticipate a significant upside.

Key Risk

If the EPS comes in above $1.90, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will either reinforce the recent positive trends or highlight potential weaknesses.

Bull Confirmed If

An EPS of $1.90 or higher would confirm strong growth and investor confidence.

Bear Confirmed If

An EPS below $1.70 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±3.35%

Historical Avg

±7.7%

Pricing cheap

The options market is pricing in a modest move of about 3.35%, suggesting that traders expect limited volatility around the earnings announcement.

Options are pricing ±3.3% while KRYS has averaged ±7.7% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

38.7%

Calls (1K)P/C Ratio: 0.13Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Krystal Biotech beats expectations, history suggests the stock could rise by an average of 2.6%, confirming a positive growth outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 14.05%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into customer adoption rates for recent therapies.
4Guidance on future revenue expectations and growth strategies.
5Details on any potential partnerships or collaborations that could enhance growth.